FindTrial
Sign In

Studying Immunity Against RSV (Respiratory Virus) in Adults Across India.

A Multicentric, Sero-epidemiological study to assess the neutralizing antibodies titer against respiratory syncytial virus (RSV-A and RSV-B) among the adult population across India. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/105877
Enrollment
250
Registered
2026-03-10
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Cipla Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. a) Individuals aged 18-49 with any of these comorbid conditions: COPD, bronchial asthma, cardiovascular diseases and diabetes mellitus b) Individuals age greater than or equal to 50 years irrespective of presence of comorbid conditions. 2. Participant or legally acceptable representative (LAR) able to provide written informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Any confirmed or suspected immuno-compromised condition based on medical history and physical examination (no laboratory testing required) 2. Pregnant & lactating females or actively breast feeding. 3. Females with positive urine pregnancy test at time of screening. 4. History of vaccination against RSV 5. Recipient of blood, plasma or platelet transfusions during last 6 months 6. History of organ transplantation. 7. History lower respiratory tract infection including RSV in last 3 months

Design outcomes

Primary

MeasureTime frame
To assess the baseline levels of neutralizing antibodies against RSV (RSV-A And RSV-B) in overall study participants across India.Timepoint: N/A—

Secondary

MeasureTime frame
To assess the baseline levels of neutralizing antibodies against RSV (RSV-A And RSV-B) in study participants by region, comorbid conditions, age & gender across India.Timepoint: N/A—

Countries

India

Contacts

Public ContactDr Sherin Eddin

Cipla Ltd Vikhroli Mumbai

Hemant.Joshi2@Cipla.com9823066463

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026